Drug news
Eylea approved by European Commission to treat Diabetic Macular Edema - Bayer/Regeneron
Bayer HealthCare announced on 11 August 2014 that Eylea (aflibercept solution for injection into the eye) has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema (DME). Bayer plans for an immediate roll-out with Germany being one of the first launch countries in Europe.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.